作者:Maoqun Tian、Aliaa Abdelrahman、Stephanie Weinhausen、Sonja Hinz、Stefanie Weyer、Stefan Dosa、Ali El-Tayeb、Christa E. Müller
DOI:10.1016/j.bmc.2013.12.035
日期:2014.2
diseases. In the present study, a series of 47 carbamazepine derivatives including 32 novel compounds were designed, synthesized, and evaluated as P2X4 receptor antagonists. Their potency to inhibit ATP-induced calcium influx in 1321N1 astrocytoma cells stably transfected with the human P2X4 receptor was determined. Additionally, species selectivity (human, rat, mouse) and receptor subtype selectivity (P2X4
P2受体亚型P2X4(一种ATP激活的阳离子通道受体)的拮抗剂作为治疗神经性疼痛和其他炎症性疾病的新型药物具有潜力。在本研究中,设计,合成了一系列47种卡马西平衍生物,包括32种新化合物,并将其评估为P2X4受体拮抗剂。确定了它们在稳定转染了人类P2X4受体的1321N1星形细胞瘤细胞中抑制ATP诱导的钙内流的能力。此外,还针对选定的衍生物研究了物种选择性(人,大鼠,小鼠)和受体亚型选择性(P2X4与P2X1、2、3、7)。表现出P2X4抑制变构机制的本系列中最有效的化合物是N,N-二异丙基-5 H-dibenz [ b,f ] azepine -5-carboxamide(34,IC 50为3.44μM)。到目前为止,本研究扩展了关于P2X4受体拮抗剂的结构-活性关系的非常有限的知识。